Literature DB >> 1242654

[Quantitative determination of cyclophosphamide, ifosfamide, and trofosfamide and their stable metabolites on TLC-plates with the aid of 4-pyridine-aldehyde-2-benzothiazolyl-hydrazone (PBH) (author's transl)].

K Norpoth, H W Addicks, U Witting, G Mŭller, H Raidt.   

Abstract

Cyclophosphamide, ifosfamide, and trofosfamide can be analysed quantitatively together with their stable alkylating urine metabolites on TL-plates by means of the PBH-reagent (4-pyridine-aldehyde-2-benzothiazolyl-hydrazone). The method requires only 0.01 ml urine, but a careful standardisation is necessary by using reference substances. The minimum measurable amounts are between 0.25 and 0.5 mug. In the urines of rat and man the carboxy derivatives and the dechloroethyl derivatives, respectively, resulting from side chain oxidation, are predominant next to cyclophosphamide, ifosfamide, or trofosfamide, respectively. Side chain oxidation can be prevalent, as we have found in some patients treated with ifosfamide. The method described allows not only the calculation of time functions for the excretion of PBH-reactive substances but also in vitro investigations of the chemokinetic properties of cyclophosphamide derivatives under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1242654

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  Comparative metabolism of cyclophosphamide and ifosfamide in the mouse using UPLC-ESI-QTOFMS-based metabolomics.

Authors:  Fei Li; Andrew D Patterson; Constance C Höfer; Kristopher W Krausz; Frank J Gonzalez; Jeffrey R Idle
Journal:  Biochem Pharmacol       Date:  2010-06-10       Impact factor: 5.858

2.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.

Authors:  J Boos; F Küpker; G Blaschke; H Jürgens
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.